1. Home
  2. ACR vs SPRO Comparison

ACR vs SPRO Comparison

Compare ACR & SPRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

ACR

ACRES Commercial Realty Corp.

HOLD

Current Price

$19.01

Market Cap

134.4M

Sector

Real Estate

ML Signal

HOLD

Logo Spero Therapeutics Inc.

SPRO

Spero Therapeutics Inc.

HOLD

Current Price

$2.58

Market Cap

124.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ACR
SPRO
Founded
2005
2013
Country
United States
United States
Employees
N/A
N/A
Industry
Real Estate Investment Trusts
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
134.4M
124.5M
IPO Year
N/A
2017

Fundamental Metrics

Financial Performance
Metric
ACR
SPRO
Price
$19.01
$2.58
Analyst Decision
Buy
Analyst Count
2
0
Target Price
$24.50
N/A
AVG Volume (30 Days)
14.2K
261.2K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$47,977,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$19.59
N/A
Revenue Growth
N/A
N/A
52 Week Low
$16.51
$0.51
52 Week High
$24.61
$3.09

Technical Indicators

Market Signals
Indicator
ACR
SPRO
Relative Strength Index (RSI) 51.37 67.53
Support Level $18.73 $2.15
Resistance Level $19.63 $2.70
Average True Range (ATR) 0.38 0.10
MACD 0.10 0.04
Stochastic Oscillator 56.92 85.85

Price Performance

Historical Comparison
ACR
SPRO

About ACR ACRES Commercial Realty Corp.

ACRES Commercial Realty Corp is a commercial real estate investment trust that focuses on originating, holding and managing commercial real estate (CRE) mortgage loans and equity investments in commercial real estate properties through direct ownership and joint ventures. The company invests in commercial real-estate-related assets, including whole loans, A notes, B notes, mezzanine loans, and mortgage-related securities, as well as commercial finance assets, which include other asset-backed securities, senior secured corporate loans, equipment leases and notes, trust preferred securities, debt tranches of collateralize debt obligations, and private equity investments mainly issued by financial institutions.

About SPRO Spero Therapeutics Inc.

Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. Besides, it is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.

Share on Social Networks: